Abstract
Prostatic lesions on routine staining sometimes cause diagnostic dilemma especially in premalignant lesions like atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia. Benign small acinar lesions also may be difficult to differentiate from small acinar adenocarcinoma. An important differentiating point is the loss of basal cell layer in adenocarcinoma and its presence in benign lesions. Basal cell markers (e.g. 34βE12 cytokeratin) & proliferative markers (e.g. AgNOR and PCNA) can help in this regard. Total 60 cases of different prostatic lesions studied. After history taking, clinical examination, radiological & other investigations were done. Routine H&E staining, immunohistochemical staining against 34βE12 cytokeratin & proliferative markers (AgNOR & PCNA) was performed. Statistically significant differences found in expression of 34βE12 cytokeratin and proliferative markers between benign, premalignant and malignant prostatic lesions. Basal cell markers and proliferative markers are important parameters to distinguish between different benign, premalignant and malignant prostatic lesions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BHP:
-
Benign hyperplasia of prostate
- AAH:
-
Atypical adenomatous hyperplasia
- PIN:
-
Prostatic intraepithelial neoplasia
- Pca:
-
Prostatic adenocarcinoma
- PSA:
-
Prostate specific antigen
- H&E:
-
Hematoxylin and Eosin stain
- 34βE12:
-
Monoclonal antibody against high molecular weight cytokeratin 34βE12
- AgNOR:
-
Silver staining nucleolar organizer regions
- PCNA:
-
Proliferating cell nuclear antigen
- DRE:
-
Digital rectal examination
References
Epstein JI (2006) The lower urinary tract and male genital system, chapter 21 In: Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease, 7th edn. Saunders, Elsevier, reprint pp 1047, 1048, 1050
O’Malley FP, Gignon DJ, Shum DT (1990) Usefulness of immunoperoxidase staining with high molecular weight cytokeratin in the differential diagnosis of small acinar lesions of prostate gland. Virchows Arch, A Pathol Anat Histopathol 417(3):191–196
Helpap B (1995) Cell kinetic studies of prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of prostate. Pathol Res Pract 191(9):904–907
Zhou M, Shah R, Shen R, Rubin MA (2003) Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol 27(3):365–371
Ghosh J, Burman A, Chatterjee A (2004) Role of proliferative markers in prostatic lesions. Indian J Pathol Microbiol 47(3):354–358
Speights VO Jr, Cohen MK, Riggs MW, Coffield KS, Keegon G, Arber DA (1997) Neuroendocrine stains & proliferative indices of prostatic adenocarcinoma in transurethral resection samples. Br J Urol 80:281–286
Kawase N (1994) Nucleolar organizer regions and PCNA expression in prostatic cancer. Pathol Int 44(3):213–222
Rennac MD, Epstein JI (1999) Immunostains in prostatic lesions. Am J Surg Pathol 23(5):567–570
Shah RB, Zhou M, LeBlanc M (2000) Comparison of the basal cell-specific markers, 34βE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 26:1161
Hedrick L, Epstein JI (1989) Use of keratin 903 as an adjunct in the diagnosis of prostate PCA. Am J Surg Pathol 13(5):389–396
Ostergaard J (2001) Monoclonal mouse antibody against high molecular weight cytokeratin Clone 34βE12, isotype IgG1, kappa. Primary antibodies and related products, DAKO catalogue, p 117, DAKO A/S, Produkionsvej 42, DK- 2600, Glostrup, Denmark
Ostergaard J (2001) Monoclonal mouse anti PCNA, Clone PC10, isotype IgG2a, kappa. Primary antibodies and related products, DAKO catalogue, p 139, DAKO A/S, Produkionsvej 42, DK-2600, Glostrup, Denmark
Miller K (1996) Immunocytochemical techniques, ch. 21. In: Bancroft JD, Stevens A (eds) Theory and practice of histochemical techniques, 4th edn. Churchill Livingstone, New York, pp 435–470
Bancroft JD, Stevens A (1996) Cytoplasmic granules, organelles and special tissues, ch. 17. In: Bancroft JD, Stevens A (eds) Theory and practice of histochemiPcal techniques, 4th edn. Churchill Livingstone, New York, p 389
Leed RD, Alison MR (1991) Variation in the occurrence of silver staining nucleolar organizer (AgNOR) in nonproliferating & proliferating tissue. J Pathol 165(1):43–51
Sakr WA, Sarkar FH, Prabhakar Sreepathi (2006) Measurement of cellular proliferation in human prostate by AgNOR, PCNA, and SPF, the prostate. Wiley InterScience, published online, 22(2):147–154, Jul
Ramos Soler D, Mayordomo Aranda E, Calatayud Blas A, Rubio Briones J, Solsona Narbón E, Llombart Bosch A (2006) Usefulness of Bcl-2 expression as a new basal cell marker in prostate disease. Actas Urol Esp 30(4):345–352
Totten RS, Heinemann MW, Hudson PB, Sproul EE, Stout AP (1953) Microscopic different diagnosis of latent carcinoma prostate. AMA Arch 55(2):131–141
Yang XJ, Lecksell K, Gaudin P, Epstein JI (1999) Rare expression of high molecular weight cytokeratin in adenocarcinoma of prostate gland, a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Pathol 23(2):145–152
Man Y-G, Zhao C, Chen X (2006) A subset of prostate basal cell lacks the expression of corresponding phenotypic markers. ScienceDirect 292(9):651–662
Samaratunga H, Singh M (1997) Distribution pattern of basal cells detected by cytokeratin 34βE12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol 21(4):435–440
Funding/ support source acknowledgement
From departmental grant.
Presentation details regarding the articles presentation venue, and awards, if any
Nil.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manna, A.K., Pathak, S., Gayen, P. et al. Study of Immunohistochemistry in Prostatic Lesions with Special Reference to Proliferation and Invasiveness. Indian J Surg 73, 101–106 (2011). https://doi.org/10.1007/s12262-010-0180-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-010-0180-7